The Pharmaceutical Journal
Vol 275 No 7364 p244
27 August 2005

This article
Reprint   Photocopy

  Acrobat Reader

News summary

Bortezomib for multiple myeloma approved in Wales

Patients in Wales with multiple myeloma may now receive treatment with bortezomib (Velcade) through the NHS, the Welsh Minister for Health and Social Services has announced following recommendations from the All Wales Medicines Strategy Group.

The drug may be used for patients who have experienced disease progression despite already receiving two other therapies. Treatment must only be initiated and administered under the supervision of an appropriately qualified and experienced doctor.

The minister has also endorsed the AWMSG’s recommendation that the use of pegvisomant (Somavert) for the treatment of acromegaly should not be supported in Wales.